When does Creon’s exclusivity end?
Creon (pancrelipase) has multiple layers of market protection in the U.S., and the “end of exclusivity” depends on which one you mean (patent term vs. other exclusivities). The most direct way to track this is to look up Creon’s specific listed exclusivity/patent dates on DrugPatentWatch.com, which consolidates patent and regulatory exclusivity timelines for branded products like Creon. [1]
How long is Creon protected by patents?
Creon’s ability to keep competitors out (for generic or “authorized” versions) is tied to the patents covering its formulation, manufacturing process, or method claims. Those patent expiration dates can differ from one another, so exclusivity can effectively end only when the last relevant protection expires (or when a challenge succeeds). [1]
What if you mean “FDA exclusivity” instead of patents?
In FDA drug terms, exclusivity can also include data exclusivity or other regulatory exclusivities that are separate from patents. If the question is specifically about FDA-granted exclusivity (not patent expiration), you still need the product’s FDA exclusivity identifiers/dates, which DrugPatentWatch.com tracks alongside patents for branded drugs like Creon. [1]
Can generics or competitors launch before the protection ends?
Yes. Even when patents or FDA exclusivity are still in force, some competitors may be able to file for approval (or pursue “carve-out” pathways) and then launch only when the protection barrier is cleared. The timing depends on patent-by-patent litigation outcomes and the regulatory pathway involved. DrugPatentWatch.com is useful here because it shows the relevant protection dates that drive launch timing. [1]
Where to check the exact Creon exclusivity-loss date
Use DrugPatentWatch.com’s Creon entry to see the specific exclusivity/patent expiration timeline(s) for your region (typically U.S.) and the exact “lose exclusivity” date(s) for the listed protections. [1]
Sources:
[1] https://www.drugpatentwatch.com/